colistin

Summary

Summary: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.

Top Publications

  1. Florescu D, Qiu F, McCartan M, Mindru C, Fey P, Kalil A. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis. 2012;54:670-80 pubmed publisher
    Experience with intravenous and aerosolized forms of colistin for the treatment of ventilator-associated pneumonia (VAP) in patients without cystic fibrosis is limited...
  2. Arpin C, Noury P, Boraud D, Coulange L, Manetti A, Andre C, et al. NDM-1-producing Klebsiella pneumoniae resistant to colistin in a French community patient without history of foreign travel. Antimicrob Agents Chemother. 2012;56:3432-4 pubmed publisher
    ..isolate produced the metallocarbapenemase NDM-1 and was resistant to all antibiotics except tetracyclines and colistin. The K...
  3. Bergen P, Tsuji B, Bulitta J, Forrest A, Jacob J, Sidjabat H, et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55:5685-95 pubmed publisher
    ..The aim of this study was to systematically investigate bacterial killing and emergence of colistin resistance with colistin and doripenem combinations against MDR P. aeruginosa...
  4. Vila Farrés X, Garcia de la Maria C, López Rojas R, Pachon J, Giralt E, Vila J. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2012;18:383-7 pubmed publisher
    At present, colistin is among the few antibiotics effective against Acinetobacter baumannii clinical isolates. However, in the last few years, colistin-resistant A. baumannii strains have been isolated...
  5. Gales A, Jones R, Sader H. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother. 2011;66:2070-4 pubmed publisher
    To comparatively evaluate the antimicrobial activities of colistin and polymyxin B with those of other antimicrobials against a worldwide collection of 40?625 Gram-negative bacilli...
  6. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19:E23-E30 pubmed publisher
    ..Overall, 36.1% and 20.4% of strains were also resistant to colistin and tigecycline, respectively...
  7. Neonakis I, Samonis G, Messaritakis H, Baritaki S, Georgiladakis A, Maraki S, et al. Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: ineffectiveness of carbapenems and increasing resistance to colistin. Chemotherapy. 2010;56:448-52 pubmed publisher
    ..Due to its increased non-susceptibility rates, Klebsiella pneumoniae has emerged as one of the most problematic pathogens...
  8. Hraiech S, Roch A, Lepidi H, Atieh T, Audoly G, Rolain J, et al. Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother. 2013;57:5120-1 pubmed publisher
    ..isogenic clinical isolates of Acinetobacter baumannii, one resistant (ABCR) and the other susceptible (ABCS) to colistin. In vitro, ABCR exhibited slower growth kinetics than ABCS...
  9. Souli M, Galani I, Boukovalas S, Gourgoulis M, Chryssouli Z, Kanellakopoulou K, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother. 2011;55:2395-7 pubmed publisher
    Using time-kill methodology, we investigated the interactions of fosfomycin with meropenem or colistin or gentamicin against 17 genetically distinct Klebsiella pneumoniae clinical isolates carrying blaKPC-2...

More Information

Publications62

  1. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141:1214-22 pubmed publisher
    The aim of this study was to compare the responses of colistin treatment alone vs. a combination of colistin and rifampicin in the treatment of ventilator-associated pneumonia (VAP) caused by a carbapenem-resistant A. baumannii strain...
  2. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52-9 pubmed publisher
    ..was administered intravenously at a median dose of 24g/day for a median of 14 days, mainly in combination with colistin or tigecycline. Clinical outcome at Day 14 was successful in 54...
  3. Docobo Pérez F, Nordmann P, Domínguez Herrera J, López Rojas R, Smani Y, Poirel L, et al. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. Int J Antimicrob Agents. 2012;39:251-4 pubmed publisher
    ..The aim of this study was to assess the efficacies of colistin and tigecycline in an experimental model of pneumonia caused by NDM-1-producing Escherichia coli and Klebsiella ..
  4. Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012;117:1335-47 pubmed publisher
    b>Colistin often remains the only active agent against multidrug-resistant Gram-negative pathogens...
  5. Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284-94 pubmed publisher
    ..of multidrug-resistant Gram-negative pathogens and the paucity of new agents to combat these infections, colistin (administered as its inactive prodrug colistin methanesulfonate [CMS]) has reemerged as a treatment option, ..
  6. Ozbek B, Sentürk A. Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii. Chemotherapy. 2010;56:466-71 pubmed publisher
    b>Colistin sulfate and levofloxacin, alone and in combination with tigecycline, were investigated for their in vitro activities and postantibiotic effects (PAEs) on6 meropenem-resistant Acinetobacter baumannii...
  7. Cannatelli A, D Andrea M, Giani T, Di Pilato V, Arena F, Ambretti S, et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother. 2013;57:5521-6 pubmed publisher
    b>Colistin is one of the few agents that retain activity against extensively drug-resistant strains of Klebsiella pneumoniae producing KPC-type carbapenemases (KPC-KP). However, resistance to colistin is increasingly reported among KPC-KP...
  8. Paksu M, Paksu S, Karadag A, Sensoy G, AsIlioglu N, Yildizdas D, et al. Old agent, new experience: colistin use in the paediatric Intensive Care Unit--a multicentre study. Int J Antimicrob Agents. 2012;40:140-4 pubmed publisher
    ..The aim of this study was to investigate the efficacy and safety of colistin therapy in paediatric patients with severe nosocomial infections caused by MDR Gram-negative bacteria...
  9. Hornsey M, Wareham D. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011;55:3534-7 pubmed publisher
    ..In this study we assessed the activities of two glycopeptide-colistin combinations both in vitro and using a Galleria mellonella caterpillar model of A. baumannii infection...
  10. Mohamed A, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56:4241-9 pubmed publisher
    A previous pharmacokinetic study on dosing of colistin methanesulfonate (CMS) at 240 mg (3 million units [MU]) every 8 h indicated that colistin has a long half-life, resulting in insufficient concentrations for the first 12 to 48 h after ..
  11. Lim L, Ly N, Anderson D, Yang J, Macander L, Jarkowski A, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30:1279-91 pubmed publisher
    b>Colistin is a polymyxin antibiotic that was discovered in the late 1940s for the treatment of gram-negative infections...
  12. Dalfino L, Puntillo F, Mosca A, Monno R, Spada M, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720-6 pubmed publisher
    Gram-negative bacteria susceptible only to colistin (COS) are emerging causes of severe nosocomial infections, reviving interest in the use of colistin...
  13. Hornsey M, Longshaw C, Phee L, Wareham D. In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother. 2012;56:3080-5 pubmed publisher
    ..Here we assessed the in vitro activity of the novel lipoglycopeptide telavancin (TLV) when combined with colistin (COL) versus 13 Gram-negative type strains and 66 clinical isolates...
  14. Vidaillac C, Benichou L, Duval R. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012;56:4856-61 pubmed publisher
    b>Colistin resistance, although uncommon, is increasingly being reported among Gram-negative clinical pathogens, and an understanding of its impact on the activity of antimicrobials is now evolving...
  15. Hinarejos P, Guirro P, Leal J, Montserrat F, Pelfort X, Sorli M, et al. The use of erythromycin and colistin-loaded cement in total knee arthroplasty does not reduce the incidence of infection: a prospective randomized study in 3000 knees. J Bone Joint Surg Am. 2013;95:769-74 pubmed publisher
    ..without antibiotic was used in 1465 knees (the control group) and a bone cement loaded with erythromycin and colistin was used in 1483 knees (the study group). All patients received the same systemic prophylactic antibiotics...
  16. Bergen P, Forrest A, Bulitta J, Tsuji B, Sidjabat H, Paterson D, et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother. 2011;55:5134-42 pubmed publisher
    ..The aim of this study was to systematically investigate in vitro bacterial killing and resistance emergence with colistin alone and in combination with imipenem against multidrug-resistant (MDR) P. aeruginosa...
  17. Moskowitz S, Brannon M, Dasgupta N, Pier M, Sgambati N, Miller A, et al. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother. 2012;56:1019-30 pubmed publisher
    ..work has shown that mutations in the PmrAB and PhoPQ regulatory systems can confer low to moderate levels of colistin (polymyxin E) resistance in laboratory strains and clinical isolates of this organism (MICs of 8 to 64 mg/liter)...
  18. Ku K, Pogue J, Moshos J, Bheemreddy S, Wang Y, Bhargava A, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control. 2012;40:983-7 pubmed publisher
    ..Study aim was to compare the efficacy of colistin to tigecycline for the treatment of these types of infections.
  19. Soon R, Nation R, Cockram S, Moffatt J, Harper M, Adler B, et al. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J Antimicrob Chemother. 2011;66:126-33 pubmed publisher
    electrostatic forces mediate the initial interaction between cationic colistin and Gram-negative bacterial cells. Lipopolysaccharide (LPS) loss mediates colistin resistance in some A. baumannii strains...
  20. Kalin G, Alp E, Coskun R, Demiraslan H, Gundogan K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?. J Infect Chemother. 2012;18:872-7 pubmed publisher
    In this study we aimed to assess the safety and efficacy of high-dose IV colistin (COL) and aerosolized COL for the treatment of Acinetobacter baumannii ventilator-associated pneumonia (VAP)...
  21. Bahador A, Taheri M, Pourakbari B, Hashemizadeh Z, Rostami H, Mansoori N, et al. Emergence of rifampicin, tigecycline, and colistin-resistant Acinetobacter baumannii in Iran; spreading of MDR strains of novel International Clone variants. Microb Drug Resist. 2013;19:397-406 pubmed publisher
    ..The drug resistance pattern showed that 14.2%, 20%, and 77% of the A. baumannii isolates were resistant to colistin, tigecycline, and rifampicin, respectively...
  22. Arnold H, Sawyer A, Kollef M. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care. 2012;57:1226-33 pubmed publisher
    ..Ninety-three patients were evaluated (NAAA n = 74, AAA n = 19, inhaled colistin n = 9, inhaled tobramycin n = 10)...
  23. Somily A, Absar M, Arshad M, Al Aska A, Shakoor Z, Fatani A, et al. Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline. Saudi Med J. 2012;33:750-5 pubmed
    To examine susceptibility of Pseudomonas aeruginosa (P. aeruginosa) and Acinetobacter baumannii (A. baumannii ) against carbapenems along with colistin and tigecycline as alternative therapeutic options.
  24. Kofteridis D, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis. 2010;51:1238-44 pubmed publisher
    ..Intravenous (IV) colistin or aerosolized (AS) plus IV colistin have been recently used to treat these life-threatening infections...
  25. Naghmouchi K, Baah J, Hober D, Jouy E, Rubrecht C, Sane F, et al. Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. Antimicrob Agents Chemother. 2013;57:2719-25 pubmed publisher
    ..The aim of this study was to assess the in vitro activity of colistin alone or in combination with two bacteriocins, nisin A and pediocin PA-1/AcH, against Salmonella choleraesuis ..
  26. Moffatt J, Harper M, Adler B, Nation R, Li J, Boyce J. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:3022-4 pubmed publisher
    ..baumannii lipid A biosynthesis genes lpxA and lpxC, resulting in the complete loss of lipopolysaccharide production and high-level colistin resistance.
  27. Marchaim D, Chopra T, Pogue J, Perez F, Hujer A, Rudin S, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother. 2011;55:593-9 pubmed publisher
    Carbapenem-resistant Klebsiella pneumoniae has spread worldwide and throughout the United States. Colistin is used extensively to treat infections with this organism. We describe a cluster of colistin-resistant, carbapenem-resistant K...
  28. Soon R, Nation R, Harper M, Adler B, Boyce J, Tan C, et al. Effect of colistin exposure and growth phase on the surface properties of live Acinetobacter baumannii cells examined by atomic force microscopy. Int J Antimicrob Agents. 2011;38:493-501 pubmed publisher
    The diminishing antimicrobial development pipeline has forced the revival of colistin as a last line of defence against infections caused by multidrug-resistant Gram-negative 'superbugs' such as Acinetobacter baumannii...
  29. Durakovic N, Radojcic V, Boban A, Mrsic M, Sertic D, Serventi Seiwerth R, et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011;50:1009-13 pubmed
    ..The aim of this study was to determine the efficacy and safety of colistin (colistimethate sodium) in the treatment of serious infections caused by MDR-PA in these patients...
  30. Ly N, Yang J, Bulitta J, Tsuji B. Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:3453-6 pubmed publisher
    The in vitro pharmacodynamics of colistin against Pseudomonas aeruginosa PAO1 wild-type and isogenic knockout strains of phoP and pmrA were evaluated...
  31. Pelletier M, Casella L, Jones J, Adams M, Zurawski D, Hazlett K, et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57:4831-40 pubmed publisher
    ..Due to the increase in MDR strains, the cationic antimicrobial peptide colistin has been used to treat A. baumannii infections. Colistin-resistant strains of A...
  32. Hood M, Becker K, Roux C, Dunman P, Skaar E. genetic determinants of intrinsic colistin tolerance in Acinetobacter baumannii. Infect Immun. 2013;81:542-51 pubmed publisher
    ..baumannii to the antibiotic colistin. Screening of a transposon mutant library identified over 30 genes involved in inducible colistin resistance in A...
  33. Karaoglan I, Zer Y, Boşnak V, Mete A, Namiduru M. In vitro synergistic activity of colistin with tigecycline or ?-lactam antibiotic/?-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. J Int Med Res. 2013;41:1830-7 pubmed publisher
    ..This study investigated the in vitro effect of various antibiotic combinations against carbapenem-resistant A. baumannii strains...
  34. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis. 2011;11:317 pubmed publisher
    b>Colistin is used as last treatment option for pneumonia associated with multidrug-resistant (MDR) Pseudomonas spp.. Literature about the best administration mode (inhalation versus parenteral treatment) is lacking...
  35. Kádár B, Kocsis B, Toth A, Damjanova I, Szász M, Kristóf K, et al. Synergistic antibiotic combinations for colistin-resistant Klebsiella pneumoniae. Acta Microbiol Immunol Hung. 2013;60:201-9 pubmed publisher
    ..The study included a colistin-susceptible and a colistin-resistant KPC-2 producing K...
  36. Sampson T, Liu X, Schroeder M, Kraft C, Burd E, Weiss D. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob Agents Chemother. 2012;56:5642-9 pubmed publisher
  37. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S, Moffatt J, et al. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-?-1,6-N-acetylglucosam. Antimicrob Agents Chemother. 2012;56:59-69 pubmed publisher
    We recently demonstrated that colistin resistance in Acinetobacter baumannii can result from mutational inactivation of genes essential for lipid A biosynthesis (Moffatt JH, et al., Antimicrob. Agents Chemother. 54:4971-4977)...
  38. López Rojas R, Domínguez Herrera J, McConnell M, Docobo Pérez F, Smani Y, Fernández Reyes M, et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis. 2011;203:545-8 pubmed publisher
    ..Collection strain 19606) acquires mutations in the pmrB gene during the in vitro development of resistance to colistin. The colistin-resistant strain has lower affinity for colistin, reduced in vivo fitness (competition index, ...
  39. Herrera M, Mobilia L, Posse G. [Comparative evaluation of the sensitivity of Acinetobacter to colistin, using the prediffusion and minimum inhibitory concentration methods: detection of heteroresistant isolates]. Rev Argent Microbiol. 2011;43:115-9 pubmed publisher
    ..of the prediffusion and minimum inhibitory concentration (MIC) methods for the detection of sensitivity to colistin, and to detect Acinetobacter baumanii-calcoaceticus complex (ABC) heteroresistant isolates to colistin...
  40. Celik I, Oguz S, Demirel G, Erdeve O, Dilmen U. Outcome of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa treated with aerosolized colistin in neonates: a retrospective chart review. Eur J Pediatr. 2012;171:311-6 pubmed publisher
    ..Older antimicrobial agents such as colistin have become life-saving drugs because of the susceptibility of these pathogens...
  41. Miller A, Brannon M, Stevens L, Johansen H, Selgrade S, Miller S, et al. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother. 2011;55:5761-9 pubmed publisher
    ..To explore the role of PhoPQ in high-level clinical polymyxin resistance, P. aeruginosa strains with colistin MICs > 512 mg/liter that had been isolated from cystic fibrosis patients treated with inhaled colistin (..
  42. Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57:3990-3 pubmed publisher
    ..of mortality and represent a major therapeutic challenge, especially when the isolates are also resistant to colistin. We used the checkerboard method to evaluate the synergistic activity of 10 antibiotic combinations against 13 ..
  43. Turkoglu M, Dizbay M, Ciftçi A, Aksakal F, Aygencel G. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. Int J Antimicrob Agents. 2012;39:142-5 pubmed publisher
    Recently, colistin has become a salvage therapy in the treatment of serious Intensive Care Unit infections owing to the emergence of extensively drug-resistant (XDR) bacterial isolates...
  44. Couet W, Gregoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect. 2012;18:30-9 pubmed publisher
    b>Colistin is a re-emerging old antibiotic that is used to treat multidrug-resistant infections in critically ill patients. It corresponds to a mixture of at least 30 different compounds administered as inactive derivatives...
  45. Wareham D, Gordon N, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 2011;66:1047-51 pubmed publisher
    ..Although a potent interaction between vancomycin and colistin has been demonstrated, there are concerns regarding the inherent toxicity of combining these agents in clinical ..
  46. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37:244-7 pubmed publisher
    ..Tigecycline alone and combined with colistin and meropenem was tested against eight genetically unrelated KPC-producing clinical strains of Enterobacteriaceae ..
  47. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother. 2010;65:2645-9 pubmed publisher
    ..an additional 4 mL of nebulized sterile normal saline (NSS) (n?=?49) or nebulized CMS equivalent to 75 mg of colistin base in 4 mL of NSS (n?=?51) every 12 h until systemic antibiotic therapy of VAP was ended...
  48. Haworth C, Foweraker J, Wilkinson P, Kenyon R, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189:975-82 pubmed publisher
    ..To perform a randomized placebo-controlled study assessing the efficacy and safety of inhaled colistin in patients with bronchiectasis and chronic P. aeruginosa infection. Patients with bronchiectasis and chronic P...
  49. Ozkan G, Ulusoy S, Orem A, Alkanat M, Mungan S, Yulug E, et al. How does colistin-induced nephropathy develop and can it be treated?. Antimicrob Agents Chemother. 2013;57:3463-9 pubmed publisher
    b>Colistin is an old antibiotic used in the treatment of Gram-negative infections. It was once suspended because of its nephrotoxic effect but has since been reintroduced due to multidrug-resistant bacterial infections...
  50. Zeidler U, Bougnoux M, Lupan A, Helynck O, Doyen A, Garcia Z, et al. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J Antimicrob Chemother. 2013;68:1285-96 pubmed publisher
    ..Here we aimed to identify compounds that act synergistically with echinocandin antifungals and that could contribute to a faster reduction of the fungal burden...
  51. Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-?-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013;57:1421-7 pubmed publisher
    ..We compared the activities of fosfomycin, tigecycline, colistin, and gentamicin (alone and in combination) against a CTX-M15-producing strain of Escherichia coli (Bj HDE-1) in ..
  52. Beceiro A, Llobet E, Aranda J, Bengoechea J, Doumith M, Hornsey M, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother. 2011;55:3370-9 pubmed publisher
    b>Colistin resistance is rare in Acinetobacter baumannii, and little is known about its mechanism...
  53. Liang W, Liu X, Huang J, Zhu D, Li J, Zhang J. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis. 2011;11:109 pubmed publisher
    ..In this study, we analyzed the in vitro activities of three colistin-based combinations and a minocycline-based combination against clinically isolated extensive drug resistant ..